醫(yī)療特長：目前主要從事腫瘤微創(chuàng)介入治療，涵蓋原發(fā)性及轉(zhuǎn)移性肝癌、肺癌、膽管癌、胰腺癌及盆腔腫瘤、骨轉(zhuǎn)移瘤等多種腫瘤的介入診療（包括動(dòng)脈灌注化療與栓塞、氬氦刀冷凍、射頻、微波消融、粒子與支架植入、輸液港植入、穿刺活檢等），及腫瘤分子靶向與免疫治療。
教育及工作經(jīng)歷：
2017年獲中山大學(xué)醫(yī)學(xué)博士學(xué)位，同年就職于中山大學(xué)附屬第一醫(yī)院腫瘤介入科，從事腫瘤介入方面工作。曾榮獲2023年度“中山大學(xué)附屬第一醫(yī)院本科教學(xué)優(yōu)秀教師”稱號，并在2024年“中山大學(xué)附屬第一醫(yī)院青年教師授課大賽”中榮獲一等獎(jiǎng)。
社會(huì)任職：
現(xiàn)任亞洲冷凍治療學(xué)會(huì)第七屆委員會(huì)委員、廣東省健康管理協(xié)會(huì)脂肪肝多學(xué)科診治專業(yè)會(huì)委員及廣東省中西結(jié)合醫(yī)學(xué)腫瘤介入治療專業(yè)委員會(huì)委員。
科研情況：
主要研究方向?yàn)楦伟┚C合治療的臨床與基礎(chǔ)研究。近年以第一作者在JAMA oncology、Radiol Med、J Cancer Res Clin等高質(zhì)量SCI雜志上發(fā)表論文13篇，單篇最高影響因子為24.79。主持國家自然科學(xué)基金青年項(xiàng)目1項(xiàng)及省部級項(xiàng)目3項(xiàng)，參與國家級及省部級項(xiàng)目多項(xiàng)。曾參與獲得廣東省科技進(jìn)步獎(jiǎng)二等獎(jiǎng)及中國抗癌協(xié)會(huì)科技獎(jiǎng)二等獎(jiǎng)。
論著：
[1]Fan W, Zhu B, Chen S, Wu Y, et al. Survival in Patients With Recurrent Intermediate-Stage Hepatocellular Carcinoma: Sorafenib Plus TACE vs TACE Alone Randomized Clinical Trial[J]. JAMA Oncol. 2024 Aug 1;10(8):1047-1054.
[2]Huang K, Liu H, Wu Y, et al. Development and validation of survival prediction models for patients with hepatocellular carcinoma treated with transcatheter arterial chemoembolization plus tyrosine kinase inhibitors[J]. Radiol Med. 2024 Nov;129(11):1597-1610.
[3]Huang K, Wu Y, Fan W, et al. Identification of BRD7 by whole-exome sequencing as a predictor for intermediate-stage hepatocellular carcinoma in patients undergoing TACE[J]. J Cancer Res Clin Oncol. 2023 Oct;149(13):11247-11261.
[4]Tang Y, Wu Y, Xue M, et al. A 10-Gene Signature Identified by Machine Learning for Predicting the Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma[J]. J Oncol. 2022 Jan 24;2022:3822773.
[5]Xue M, Wu Y, Zhu B, et al. Advanced hepatocellular carcinoma treated by transcatheter arterial chemoembolization with drug-eluting beads plus lenvatinib versus sorafenib, a propensity score matching retrospective study[J]. Am J Cancer Res. 2021 Dec 15;11(12):6107-6118.
[6]Wu YQ, Fan WZ, Xue M, et al. 25-OH-vitamin D deficiency identifies poor tumor response in hepatocellular carcinoma treated with transarterial chemoembolization[J]. Clin Transl Oncol. 2020 Jan;22(1):70-80.
[7]Ye J, Wu Y, Li M, et al. Keratin 8 Mutations Were Associated With Susceptibility to Chronic Hepatitis B and Related Progression[J]. J Infect Dis. 2020 Jan 14;221(3):464-473.
[8]Zhu B, Wu Y, Niu L, et al. Silencing SAPCD2 Represses Proliferation and Lung Metastasis of Fibrosarcoma by Activating Hippo Signaling Pathway[J]. Front Oncol. 2020 Dec 15;10:574383.
[9]Xue M, Wu Y, Fan W, et al. Prognostic Value of?TP53?Mutation?for Transcatheter Arterial Chemoembolization?Failure/Refractoriness in HBV-Related Advanced Hepatocellular Carcinoma[J]. Cancer Res Treat. 2020 Jul;52(3):925-937.
[10]Wu Y, Fan W, Xue M, et al. Postintervention Interleukin-6 (IL-6) Level, Rather than the Pretreatment or Dynamic Changes of IL-6, as an Early Practical Marker of Tumor Response in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization[J]. Oncologist. 2019 Dec;24(12):e1489-e1495.
[11]Fan W, Wu Y, Lu M, et al. A meta-analysis of the efficacy and safety of iodine [131I] metuximab infusion combined with TACE for treatment of hepatocellular carcinoma[J]. Clin Res Hepatol Gastroenterol. 2019 Aug;43(4):451-459.
[12]Ye J, Wu Y, Li F, et al. Effect of orlistat on liver fat content in patients with nonalcoholic fatty liver disease with obesity: assessment using magnetic resonance imaging-derived proton density fat fraction[J]. Therap Adv Gastroenterol. 2019 Sep 26;12:1756284819879047.
[13]Wu Y, Zheng S, Yao J, et al. Decreased expression of protocadherin 20 is associated with poor prognosis in hepatocellular carcinoma[J]. Oncotarget. 2017 Jan 10;8(2):3018-3028.
